


Spotlight On: Adalimumab


August 31, 2020

Adalimumab Timeline




VENABLE | Fitzpatrick

Adalimumab Challenged Claim Types in IPR and Litigation*



VENABLE | Fitzpatrick


Adalimumab IPR Status



VENABLE | Fitzpatrick


*Considering IPR2017-00826 and IPR2017-01008 as one IPR, and IPR2017-00827 and IPR2017-01009 as one IPR.

Adalimumab Method of Treatment Claim IPR Status



VENABLE | Fitzpatrick

Adalimumab Formulation Claim IPR Status



VENABLE | Fitzpatrick

*Considering IPR2017-00826 and IPR2017-01008 as one IPR, and IPR2017-00827 and IPR2017-01009 as one IPR.

FWD = Final Written Decision

Spotlight On: Adalimumab

August 31, 2020

Technology: Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor alpha (TNFα). TNFα is a cytokine cell signaling protein that is involved in the inflammatory response that occurs in autoimmune diseases.

	<i>AbbVie v. Amgen</i> 1:16-cv-00666 (D. Del.) Settled	<i>AbbVie v. Boehringer Ingelheim</i> 1:17-cv-01065 (D. Del.) Settled	<i>Amgen v. AbbVie</i> IPR2015-01514 Institution denied	<i>Amgen v. AbbVie</i> IPR2015-01517 Institution denied
8,663,945	x			
8,911,964	x			
8,916,157	x		x	
8,916,158				x
8,926,975		x		
8,961,973	x			
8,986,693	x			
9,018,361		x		
9,090,867		x		
9,096,666	x	x		
9,220,781	x			
9,255,143		x		
9,266,949		x		
9,272,041	x	x		
9,359,434	x			
9,365,645	x			
9,546,212		x		
	<i>Coherus v. AbbVie</i> IPR2016-00172 FWD: All claims unpatentable; Appeal No. 17-2304 Affirmed (U.S. as Intervenor, Coherus settled)	<i>Boehringer Ingelheim v. AbbVie</i> IPR2016-00408, IPR2016-00409 FWD: All claims unpatentable; Appeal Nos. 17-2362 and 17-2363 Affirmed (U.S. as Intervenor, Boehringer Ingelheim settled)	<i>Coherus v. AbbVie</i> IPR2016-00188 FWD: All claims unpatentable; Appeal No. 17-2305 Affirmed (U.S. as Intervenor, Coherus settled)	<i>Coherus v. AbbVie</i> IPR2016-00189 FWD: All claims unpatentable; Appeal No. 17-2306 Affirmed (U.S. as Intervenor, Coherus settled)
8,889,135	x	x		
9,017,680			x	
9,073,987				x

	<i>Coherus v. AbbVie</i> IPR2017-00822, IPR2017-00823 Institution denied	<i>Coherus v. AbbVie</i> IPR2017-00826 / IPR2017-01008 Institution denied	<i>Coherus v. AbbVie</i> IPR2017-00827 / IPR2017-01009 Institution denied
9,085,619	x	x	x
	<i>Sandoz v. AbbVie</i> IPR2017-01823 Institution denied	<i>Sandoz v. AbbVie</i> IPR2017-01987 Institution denied; Settled during request for rehearing	<i>Sandoz v. AbbVie</i> IPR2017-01988 Institution denied; Settled during request for rehearing
8,802,100	x		
8,911,737		x	
8,974,790			x
	<i>Sandoz v. AbbVie</i> IPR2017-02106 Settled after institution	<i>Sandoz v. AbbVie</i> IPR2017-02105 Settled after institution	<i>Coherus v. AbbVie</i> IPR2016-01018 Institution denied
9,067,992	x		
9,090,689		x	
9,114,166			x
	<i>Sandoz v. AbbVie</i> IPR2017-01824 Institution denied; Request for rehearing denied; Appeal No. 18-2142 settled		<i>Sandoz v. AbbVie</i> IPR2018-00002 Institution denied; Appeal No. 18-2143 settled
9,512,216	x		x
	<i>Sandoz v. AbbVie</i> IPR2018-00156 Institution denied	<i>AbbVie v. Sandoz</i> 3:18-cv-12668 (D.N.J.) Settled	<i>Coherus v. Amgen</i> [Related to Amjevita™] 1:19-cv-00139 (D. Del.) Settled
9,187,559	x	x	
9,750,808		x	
10,155,039			x
10,159,732			x
10,159,733			x
10,207,000			x

FWD = Final Written Decision